Research programme: CNS disorder therapeutics - Taisho/Merck

Drug Profile

Research programme: CNS disorder therapeutics - Taisho/Merck

Alternative Names: MGS 0008; MGS 0028; MGS 0210

Latest Information Update: 23 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taisho Pharmaceutical
  • Developer Merck & Co; Taisho Pharmaceutical
  • Class Dicarboxylic acids
  • Mechanism of Action Metabotropic glutamate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder; Schizophrenia

Most Recent Events

  • 31 Oct 2006 Preclinical trials in Anxiety disorders in Japan (Intraperitoneal)
  • 31 Oct 2006 Preclinical trials in Depression in Japan (Intraperitoneal, PO)
  • 31 Oct 2006 Data presented at the 36th Annual Meeting of the Society for Neuroscience (SfN-2006) have been added to the Affective Disorders and Anxiety Disorders pharmacodynamics sections and the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top